kidney disease

Exaluren has FDA IND clearance for nonsense-mutation ADPKD, opening US sites for the EXPRESS Phase 2 trial of about 60 patients from Q3 2027.

Ultomiris has won FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, based on a 43.4% placebo-adjusted cut at week 34.